Johnson & Johnson JNJ hosted its annual analyst day earlier this week. Credit Suisse didn't see anything materially changing their view of the company's stock, but still had some notable takeaways.
- "Strong commitment to broad footprint."
- "Technology, innovation and business development overarching themes of the day."
- "Consumer topline performance improving, with margin expansion likely to follow."
- "JNJ also expecting accelerating market growth in Medical Devices."
- "Attention now shifts back to Pharma at ASCO."
Credit Suisse holds a Neutral rating and $112 price target on shares. The stock closed Thursday at $112.85, down 0.6 percent.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in